Carrum Health expanded its bundled cancer care reach through an alliance with City of hope, one of the largest cancer research and treatment organizations in the United States. First launched on the East Coast last year, Carrum Health is now offering its comprehensive, fixed-price package for treating non-metastatic breast cancer for the first time, including a two-year care guarantee, at City of Hope facilities throughout Southern California. This includes more than 35 convenient locations, including the newly opened Lennar Foundation Cancer Center in Orange County.
“Cancer treatment has historically not been included in bundled payments because of the length of treatment and the complexity of the cases. But we know they’re the most important for self-insured employers trying to keep up with rising health care costs and access the best quality of care for their employees,” said Sach Jain, CEO and founder of Carrum Health. “Carrum Health alleviates these concerns with the only value-based bundled payment programs for oncology. Since launching the industry’s first comprehensive cancer care package last year, we’ve seen strong demand from employers looking to offer their employees access to the best cancer specialists closer to home. We are proud to work with City of Hope to make this a reality.”
With Carrum Health’s cancer care package, patients with non-metastatic breast cancer can be eligible for up to two years of treatment at City of Hope, including excisional surgery, chemotherapy, radiation therapy, care for treatment-related complications and interdisciplinary review . inclusions and follow-ups.
What is a super app? Rather than being built to do one thing well, a super app can run many offerings in a standalone environment. A recent article by The Wall Street Journal titled What the heck is a “super app” and why are Elon Musk, Evan Spiegel, and Jack Dorsey so interested? offers this description of WeChat, a super app from a Chinese internet company:
“It started as a cross between a messaging app and a social environment, but has grown to encompass everything from ride hailing and e-commerce to mobile payments and government services. Today, it has nearly 1.3 billion users.”
In a recent blog post by Beth Strobusch, Equiva‘c head of marketing, asked, “What might a super health app look like?”
Strohbusch acknowledged that innovations in digital health have brought value to consumers and clinicians, but “there are simply too many options available today,” she said.
According to the Human Data Institute IQVIA 2021 Trends Report, more than 90,000 digital health apps were added to app stores in 2020 – an average of 250+ per day. Apps focused on managing specific diseases or health conditions, rather than health management, made up 47% of apps, up from 28% in 2015.
In healthcare, widespread adoption of disposable applications and devices is not realistic or sustainable. Equiva delivers a fresh ‘super app’ approach with its point solution aggregation and software delivery environment that securely powers any number of education and engagement solutions through mobile devices, kiosks, digital signage and more.
Carefeed, a company that offers secure, cloud-based and HIPAA-compliant digital communications solutions, closed a $3 million funding round led by Reformation Partners. Existing investors Allos Ventures and M25 also participated in the round. The investment enables Carefeed to accelerate the adoption of its platform by skilled nursing and senior living communities in the US and Canada, expand its suite of solutions and expand into other patient care settings.
To read more, Press here.
BrainCheck Inc., developer of an innovative platform for digital cognitive assessment and care, announced a researcher-initiated grant program to help fund research into the assessment, diagnosis, treatment and care of brain-related diseases. Among the conditions of interest are: Alzheimer’s disease and related dementias, post-operative delirium, stroke, traumatic brain injury and post-acute Covid ‘brain fog’. Awardees will receive one year of research funding and free access to the BrainCheck platform.
To read more, Press here.
Immunis Inc., a biotech startup developing a new treatment for age-related immune decline and disease, has raised $10 million as part of a Series A round. Remiges Ventures led the funding round with participation from several other healthcare investment firms. Proceeds will be used to support the clinical evaluation of Immunis’ immunomodulatory secretome product in a Phase 1/2a clinical trial targeting muscular atrophy, a condition associated with age, disuse and disease.
To read more, Press here.
Atropos Health, which gives doctors research-grade real-world evidence at the point of care, announced the completion of a $14 million Series A funding round. The company will use the funding to expand its sales team and continue to develop its oncology product. Breyer Capital led the round with participation from Emerson Collective and Boston Millennia Partners.
As part of the funding round, Atropos appointed Matt Bettenville of Emerson Collective to the board of directors of Atropos Health. Breyer Capital also won board seats.
To read more, Press here.
photo: akindo, Getty Images